600572 康恩贝
已收盘 04-15 15:00:00
资讯
新帖
简况
4月15日康恩贝（600572）龙虎榜数据：北向资金净卖出3528.59万元
证券之星 · 17:21
4月15日康恩贝（600572）龙虎榜数据：北向资金净卖出3528.59万元
国办一纸文件定调药价，创新药爆发！涨停名单还在拉长
格隆汇 · 14:33
国办一纸文件定调药价，创新药爆发！涨停名单还在拉长
康恩贝最新公告：子公司替米沙坦氨氯地平片（Ⅱ）获药品注册证书
证券之星 · 04-09
康恩贝最新公告：子公司替米沙坦氨氯地平片（Ⅱ）获药品注册证书
每周股票复盘：康恩贝（600572）一季度行权232.62万股
证券之星 · 04-05
每周股票复盘：康恩贝（600572）一季度行权232.62万股
康恩贝（600572）披露2026年第一季度股票期权激励计划自主行权结果暨股份变动公告，4月2日股价上涨0.9%
证券之星 · 04-02
康恩贝（600572）披露2026年第一季度股票期权激励计划自主行权结果暨股份变动公告，4月2日股价上涨0.9%
股市必读：康恩贝（600572）3月23日收盘跌6.02%，主力净流出2795.55万元
证券之星 · 03-24
股市必读：康恩贝（600572）3月23日收盘跌6.02%，主力净流出2795.55万元
每周股票复盘：康恩贝（600572）集团减持股份685.67万股
证券之星 · 03-15
每周股票复盘：康恩贝（600572）集团减持股份685.67万股
3月10日康恩贝发布公告，股东减持685.67万股
证券之星 · 03-10
3月10日康恩贝发布公告，股东减持685.67万股
3月6日康恩贝发布公告，股东减持3081.95万股
证券之星 · 03-06
3月6日康恩贝发布公告，股东减持3081.95万股
每周股票复盘：康恩贝（600572）股东减持2166万股占比0.854%
证券之星 · 03-01
每周股票复盘：康恩贝（600572）股东减持2166万股占比0.854%
2月27日康恩贝发布公告，股东减持2166.05万股
证券之星 · 02-27
2月27日康恩贝发布公告，股东减持2166.05万股
康恩贝最新公告：子公司艾司奥美拉唑镁肠溶胶囊获得药品注册证书
证券之星 · 02-26
康恩贝最新公告：子公司艾司奥美拉唑镁肠溶胶囊获得药品注册证书
康恩贝（600572）披露子公司部分药品在国家组织集采接续采购中拟中选，2月24日股价上涨0.68%
证券之星 · 02-24
康恩贝（600572）披露子公司部分药品在国家组织集采接续采购中拟中选，2月24日股价上涨0.68%
每周股票复盘：康恩贝（600572）子公司11药品拟中选集采
证券之星 · 02-15
每周股票复盘：康恩贝（600572）子公司11药品拟中选集采
康恩贝最新公告：子公司部分药品拟中选国家集采药品协议期满品种接续采购
证券之星 · 02-12
康恩贝最新公告：子公司部分药品拟中选国家集采药品协议期满品种接续采购
每周股票复盘：胡季强减持康恩贝（600572）0.941%股份
证券之星 · 02-08
每周股票复盘：胡季强减持康恩贝（600572）0.941%股份
2月6日康恩贝发布公告，股东减持2385.45万股
证券之星 · 02-06
2月6日康恩贝发布公告，股东减持2385.45万股
康恩贝(600572.SH)子公司TFA003片获得药物临床试验批准通知书
智通财经 · 02-04
康恩贝(600572.SH)子公司TFA003片获得药物临床试验批准通知书
康恩贝（600572）披露2026年度日常关联交易预计议案，2月2日股价下跌0.67%
证券之星 · 02-02
康恩贝（600572）披露2026年度日常关联交易预计议案，2月2日股价下跌0.67%
每周股票复盘：胡季强减持康恩贝（600572）0.763%股份
证券之星 · 02-01
每周股票复盘：胡季强减持康恩贝（600572）0.763%股份
加载更多
公司概况
公司名称：
浙江康恩贝制药股份有限公司
所属行业：
医药制造业
上市日期：
2004-04-12
主营业务：
浙江康恩贝制药股份有限公司的主营业务是药品、中药饮片及大健康产品的研发、制造及销售。公司的主要产品是中成药、中药材与中药饮片、中药保健品及中药提取物、中药OTC及中药处方药业务。
发行价格：
8.25
{"stockData":{"symbol":"600572","market":"SH","secType":"STK","nameCN":"康恩贝","latestPrice":4.8,"timestamp":1776236400000,"preClose":4.36,"halted":0,"volume":207486572,"delay":0,"changeRate":0.1009,"floatShares":2530000000,"shares":2537000000,"eps":0.2712,"marketStatus":"已收盘","change":0.44,"latestTime":"04-15 15:00:00","open":4.37,"high":4.8,"low":4.35,"amount":966000000,"amplitude":0.1032,"askPrice":0,"askSize":0,"bidPrice":4.8,"bidSize":174368,"shortable":0,"etf":0,"ttmEps":0.2712,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776303000000},"marketStatusCode":5,"adr":0,"adjPreClose":4.36,"symbolType":"stock","openAndCloseTimeList":[[1776216600000,1776223800000],[1776229200000,1776236400000]],"highLimit":4.8,"lowLimit":3.92,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2536895141,"isCdr":false,"pbRate":1.72,"roa":"--","peRate":17.699115,"roe":"8.05%","epsLYR":0.25,"committee":0,"marketValue":12177000000,"turnoverRate":0.082,"status":0,"floatMarketCap":12145000000},"requestUrl":"/m/hq/s/600572","defaultTab":"news","newsList":[{"id":"2627400322","title":"4月15日康恩贝（600572）龙虎榜数据：北向资金净卖出3528.59万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627400322","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627400322?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:21","pubTimestamp":1776244875,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年4月15日公布的交易公开信息显示，康恩贝因有价格涨跌幅限制的日收盘价格涨幅偏离值达到7%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年4月15日收盘，康恩贝报收于4.8元，上涨10.09%，涨停，换手率8.2%，成交量207.49万手，成交额9.66亿元。从龙虎榜公布的当日买卖数据来看，北向资金合计净卖出3528.59万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500031276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0028","600572","BK0060","BK0097","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627405121","title":"国办一纸文件定调药价，创新药爆发！涨停名单还在拉长","url":"https://stock-news.laohu8.com/highlight/detail?id=2627405121","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627405121?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:33","pubTimestamp":1776234822,"startTime":"0","endTime":"0","summary":"政策组合拳出击","market":"fut","thumbnail":"https://img3.gelonghui.com/a401d-f3f18d25-b1d2-4d82-b91d-544aa33cb569.jpg?guru_height=718&guru_width=1280&guru_size=112216","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/a401d-f3f18d25-b1d2-4d82-b91d-544aa33cb569.jpg?guru_height=718&guru_width=1280&guru_size=112216"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4422353","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["600267","000788","159992","BK0239","BK0122","BK0132","BK0028","BK0197","600488","02162","BK0250","000919","BK0012","002589","BK0097","BK0077","301408","BK1574","BK1161","600572","BK0185","06978","BK0060","BK0096","BK0102","BK1583","002038","06990","BK0070","LU0196878994.USD","BK0209","BK0188","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626423188","title":"康恩贝最新公告：子公司替米沙坦氨氯地平片（Ⅱ）获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2626423188","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626423188?lang=zh_cn&edition=full","pubTime":"2026-04-09 17:30","pubTimestamp":1775727022,"startTime":"0","endTime":"0","summary":"康恩贝(600572.SH)公告称，公司全资子公司杭州康恩贝近日收到国家药监局核准签发的替米沙坦氨氯地平片(Ⅱ)《药品注册证书》。该药品为化学药品4类，视同通过仿制药一致性评价，主要用于治疗原发性高血压。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900027728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572","BK0097","BK0188","BK0012","BK0028","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625616593","title":"每周股票复盘：康恩贝（600572）一季度行权232.62万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625616593","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625616593?lang=zh_cn&edition=full","pubTime":"2026-04-05 01:54","pubTimestamp":1775325251,"startTime":"0","endTime":"0","summary":"公司公告汇总关于2022年股票期权激励计划限制行权期间的提示性公告浙江康恩贝制药股份有限公司根据相关规定，因2025年年度报告和2026年第一季度报告披露计划，对2022年股票期权激励计划处于自主行权期的股票期权实施限制行权。关于2026年第一季度股票期权激励计划自主行权结果暨股份变动公告浙江康恩贝制药股份有限公司2022年股票期权激励计划在2026年第一季度实现自主行权，行权股票数量为232.62万股，占首次授予第二个行权期可行权总量的61.48%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572","BK0239","BK0060","BK0028","BK0012","BK0188","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624071505","title":"康恩贝（600572）披露2026年第一季度股票期权激励计划自主行权结果暨股份变动公告，4月2日股价上涨0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624071505","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624071505?lang=zh_cn&edition=full","pubTime":"2026-04-02 22:24","pubTimestamp":1775139863,"startTime":"0","endTime":"0","summary":"截至2026年4月2日收盘，康恩贝报收于4.5元，较前一交易日上涨0.9%，最新总市值为114.16亿元。公司于近日披露《关于2026年第一季度股票期权激励计划自主行权结果暨股份变动公告》。公告显示，浙江康恩贝制药股份有限公司2022年股票期权激励计划在2026年第一季度实现自主行权，行权股票数量为232.62万股，占首次授予第二个行权期可行权总量的61.48%。股本结构变动后，总股本增加2,326,200股，公司实际控制人未发生变化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200042527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0060","BK0097","BK0239","600572","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621608351","title":"股市必读：康恩贝（600572）3月23日收盘跌6.02%，主力净流出2795.55万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621608351","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621608351?lang=zh_cn&edition=full","pubTime":"2026-03-24 01:21","pubTimestamp":1774286469,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，康恩贝报收于4.06元，下跌6.02%，换手率2.75%，成交量69.48万手，成交额2.88亿元。来自交易信息汇总：当日主力资金净流出2795.55万元，占总成交额9.7%。交易信息汇总股价提醒3月23日康恩贝收盘报4.06元，跌6.02%，当日成交6948.3万元。根据收盘数据统计，该股已连续4日下跌。前10个交易日资金流向情况：主力资金累计净流出1.22亿元，股价累计下跌6.49%；融资余额累计减少4164.88万元，融券余量累计减少6.12万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400001422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","600572","BK0239","BK0097","BK0012","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619712703","title":"每周股票复盘：康恩贝（600572）集团减持股份685.67万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2619712703","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619712703?lang=zh_cn&edition=full","pubTime":"2026-03-15 01:41","pubTimestamp":1773510071,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，康恩贝报收于4.44元，较上周的4.36元上涨1.83%。本周关注点股本股东变化：股东康恩贝集团有限公司减持685.67万股，占总股本0.2703%。减持后康恩贝集团持有公司股份153,172,851股，持股比例降至6.0383%。康恩贝集团及胡季强合计持股比例由9.5636%降至6.4325%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0012","BK0028","600572","BK0060","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618939864","title":"3月10日康恩贝发布公告，股东减持685.67万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618939864","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618939864?lang=zh_cn&edition=full","pubTime":"2026-03-10 18:01","pubTimestamp":1773136874,"startTime":"0","endTime":"0","summary":"证券之星消息，3月10日康恩贝发布公告《康恩贝:关于股东减持股份结果的公告》，其股东康恩贝集团有限公司于2026年3月7日至2026年3月10日间合计减持685.67万股，占公司目前总股本的0.2703%，变动期间该股股价上涨0.23%，截止3月10日收盘报4.37元。股东增减持详情见下表：根据康恩贝2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000029382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","600572","BK0239","BK0097","BK0012","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617687815","title":"3月6日康恩贝发布公告，股东减持3081.95万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617687815","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617687815?lang=zh_cn&edition=full","pubTime":"2026-03-06 20:01","pubTimestamp":1772798470,"startTime":"0","endTime":"0","summary":"证券之星消息，3月6日康恩贝发布公告《康恩贝:关于持股5%以上股东权益变动触及1%刻度的提示性公告》，其股东胡季强、康恩贝集团有限公司于2026年3月2日至2026年3月6日间合计减持3081.95万股，占公司目前总股本的1.2151%，变动期间该股股价下跌2.68%，截止3月6日收盘报4.36元。股东增减持详情见下表：根据康恩贝2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600035750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0188","BK0012","BK0028","BK0239","600572","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616843041","title":"每周股票复盘：康恩贝（600572）股东减持2166万股占比0.854%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843041","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843041?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:25","pubTimestamp":1772303112,"startTime":"0","endTime":"0","summary":"本周关注点股本股东变化：股东胡季强减持2166.05万股，占总股本0.8541%。股本股东变化股东增减持2月27日康恩贝发布公告，其股东胡季强于2026年2月10日至2月27日间合计减持2166.05万股，占公司目前总股本的0.8541%，变动期间该股股价下跌1.32%，截止2月27日收盘报4.48元。2026年2月10日至2月27日，胡季强通过集中竞价交易方式减持公司股份21,660,500股，占公司总股本的0.854%，减持后合计持股比例由8.772%降至7.918%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0060","BK0188","BK0239","600572","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614282839","title":"2月27日康恩贝发布公告，股东减持2166.05万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2614282839","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614282839?lang=zh_cn&edition=full","pubTime":"2026-02-27 18:01","pubTimestamp":1772186468,"startTime":"0","endTime":"0","summary":"证券之星消息，2月27日康恩贝发布公告《康恩贝:关于持股5%以上股东权益变动触及1%刻度的提示性公告》，其股东胡季强于2026年2月10日至2026年2月27日间合计减持2166.05万股，占公司目前总股本的0.8541%，变动期间该股股价下跌1.32%，截止2月27日收盘报4.48元。股东增减持详情见下表：根据康恩贝2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700030613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572","BK0028","BK0239","BK0188","BK0060","BK0012","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614016042","title":"康恩贝最新公告：子公司艾司奥美拉唑镁肠溶胶囊获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2614016042","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614016042?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:23","pubTimestamp":1772097832,"startTime":"0","endTime":"0","summary":"康恩贝(600572.SH)公告称，公司全资子公司金华康恩贝收到国家药监局核准签发的艾司奥美拉唑镁肠溶胶囊《药品注册证书》，规格为20mg、40mg，注册分类为化学药品3类。该药品是《国家基本医疗保险、工伤保险和生育保险药品目录（2025年版）》乙类药品，2024年国内零售和医疗终端市场销售金额共计30.52亿元。金华康恩贝已投入研发费用约1,240万元。该药品的获批将对公司业绩产生积极影响，但未来产品销售及收入存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600026465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0239","BK0028","BK0060","BK0188","600572","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613479018","title":"康恩贝（600572）披露子公司部分药品在国家组织集采接续采购中拟中选，2月24日股价上涨0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613479018","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613479018?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:59","pubTimestamp":1771930750,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，康恩贝报收于4.46元，较前一交易日上涨0.68%，最新总市值为113.11亿元。该股当日开盘4.45元，最高4.47元，最低4.44元，成交额达1.16亿元，换手率为1.02%。近日，康恩贝发布《关于子公司部分药品在国家组织集采药品协议期满品种接续采购中拟中选的公告》。本次接续采购周期自中选结果执行日起至2028年12月31日。后续购销合同签订及市场销售存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400037823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0060","BK0188","BK0028","BK0239","600572","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611143457","title":"每周股票复盘：康恩贝（600572）子公司11药品拟中选集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2611143457","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611143457?lang=zh_cn&edition=full","pubTime":"2026-02-15 01:38","pubTimestamp":1771090691,"startTime":"0","endTime":"0","summary":"截至2026年2月13日收盘，康恩贝报收于4.43元，较上周的4.54元下跌2.42%。本周，康恩贝2月9日盘中最高价报4.58元。康恩贝当前最新总市值112.35亿元，在中药板块市值排名20/67，在两市A股市值排名1847/5189。本周关注点公司公告汇总：子公司11个药品在国家集采接续采购中拟中选，周期至2028年12月31日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021500000355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0239","BK0028","BK0060","600572","BK0188","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610920017","title":"康恩贝最新公告：子公司部分药品拟中选国家集采药品协议期满品种接续采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2610920017","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610920017?lang=zh_cn&edition=full","pubTime":"2026-02-12 23:20","pubTimestamp":1770909659,"startTime":"0","endTime":"0","summary":"康恩贝(600572.SH)公告称，公司下属子公司杭州康恩贝制药有限公司、浙江金华康恩贝生物制药有限公司参加了国家组织集采第1-8批协议期满品种接续采购的申报，公司盐酸坦索罗辛缓释胶囊、注射用哌拉西林钠他唑巴坦钠、泮托拉唑钠肠溶片等11个药品中选本次接续采购。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200039502.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0012","BK0097","BK0188","BK0028","600572"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609234965","title":"每周股票复盘：胡季强减持康恩贝（600572）0.941%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2609234965","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609234965?lang=zh_cn&edition=full","pubTime":"2026-02-08 01:19","pubTimestamp":1770484749,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，康恩贝报收于4.54元，较上周的4.51元上涨0.67%。本周关注点股本股东变化：股东胡季强减持康恩贝2385.45万股，占总股本0.941%。公司公告汇总：子公司杭州康恩贝获TFA003片临床试验批准，用于糖尿病肾病治疗。股本股东变化股东增减持2月6日，康恩贝发布公告，股东胡季强于2026年1月27日至2月5日合计减持2385.45万股，占公司总股本的0.9406%。2月7日公告显示，胡季强及其一致行动人康恩贝集团有限公司合计持股比例由9.714%降至8.774%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0060","BK0028","BK0097","BK0239","BK0188","600572"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609561994","title":"2月6日康恩贝发布公告，股东减持2385.45万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2609561994","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609561994?lang=zh_cn&edition=full","pubTime":"2026-02-06 18:01","pubTimestamp":1770372071,"startTime":"0","endTime":"0","summary":"证券之星消息，2月6日康恩贝发布公告《康恩贝:关于持股5%以上股东权益变动触及1%刻度的提示性公告》，其股东胡季强于2026年1月27日至2026年2月5日间合计减持2385.45万股，占公司目前总股本的0.9406%，变动期间该股股价下跌3.2%，截止2月5日收盘报4.54元。股东增减持详情见下表：根据康恩贝2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600030648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572","BK0097","BK0239","BK0028","BK0012","BK0188","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608351739","title":"康恩贝(600572.SH)子公司TFA003片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2608351739","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608351739?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:17","pubTimestamp":1770196622,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康恩贝(600572.SH)发布公告，近日，公司全资子公司杭州康恩贝制药有限公司(简称“杭州康恩贝”)收到国家药品监督管理局核准签发的TFA003片的《药物临床试验批准通知书》。审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025年10月16日受理的TFA003片符合药品注册的有关要求，在进一步完善临床试验方案的基础上，同意本品开展用于糖尿病肾脏疾病的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0097","BK0028","BK0012","BK0239","600572","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608018867","title":"康恩贝（600572）披露2026年度日常关联交易预计议案，2月2日股价下跌0.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608018867","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608018867?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:38","pubTimestamp":1770043103,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，康恩贝报收于4.48元，较前一交易日下跌0.67%，最新总市值为113.61亿元。近日，浙江康恩贝制药股份有限公司披露《康恩贝2026年第一次临时股东会会议材料》，拟提交《关于公司2026年度日常关联交易预计的议案》。公告显示，公司预计2026年与英特集团、康恩贝集团及珍视明公司发生日常关联交易总额不超过117,131万元。该事项需提交股东大会审议，关联股东需回避表决。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200039456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0097","BK0060","BK0239","600572","BK0188","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608072738","title":"每周股票复盘：胡季强减持康恩贝（600572）0.763%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2608072738","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608072738?lang=zh_cn&edition=full","pubTime":"2026-02-01 01:56","pubTimestamp":1769882172,"startTime":"0","endTime":"0","summary":"本次权益变动后，胡季强及其一致行动人康恩贝集团合计持股比例由10.480%下降至9.717%，权益变动比例触及1%刻度。胡季强先生与康恩贝集团合计持有公司股份242,529,556股，占总股本9.564%，累计质押股份占合计持股的17.804%，占公司总股本1.703%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0060","BK0097","BK0239","600572","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776250171870,"stockEarnings":[{"period":"1week","weight":-0.0113},{"period":"1month","weight":-0.018},{"period":"3month","weight":-0.0333},{"period":"6month","weight":-0.0268},{"period":"1year","weight":0.022},{"period":"ytd","weight":-0.0224}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":-0.0168},{"period":"3month","weight":-0.0241},{"period":"6month","weight":0.0282},{"period":"1year","weight":0.2341},{"period":"ytd","weight":0.0146}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江康恩贝制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"84321人(较上一季度减少1.11%)","perCapita":"30006股","listingDate":"2004-04-12","address":"浙江省金华市兰溪市康恩贝大道1号","registeredCapital":"253689万元","survey":" 浙江康恩贝制药股份有限公司的主营业务是药品、中药饮片及大健康产品的研发、制造及销售。公司的主要产品是中成药、中药材与中药饮片、中药保健品及中药提取物、中药OTC及中药处方药业务。","listedPrice":8.25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康恩贝(600572)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康恩贝(600572)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康恩贝,600572,康恩贝股票,康恩贝股票老虎,康恩贝股票老虎国际,康恩贝行情,康恩贝股票行情,康恩贝股价,康恩贝股市,康恩贝股票价格,康恩贝股票交易,康恩贝股票购买,康恩贝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康恩贝(600572)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康恩贝(600572)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}